---
title: "Understanding the Market | MICROPORT rises over 6% again, accumulating more than 70% increase in the past seven days after Shanghai state-owned assets acquired shares and management increased their holdings"
description: "MicroPort Medical continues to rise over 6%, with a cumulative increase of over 70% in the past seven trading days. As of the time of writing, it is up 2.11%, priced at HKD 14.52, with a trading volum"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251095929.md"
published_at: "2025-08-01T01:52:04.000Z"
---

# Understanding the Market | MICROPORT rises over 6% again, accumulating more than 70% increase in the past seven days after Shanghai state-owned assets acquired shares and management increased their holdings

> MicroPort Medical continues to rise over 6%, with a cumulative increase of over 70% in the past seven trading days. As of the time of writing, it is up 2.11%, priced at HKD 14.52, with a trading volume of HKD 266 million. In terms of news, on July 25th, MicroPort Medical's largest shareholder, Otsuka Medical Devices, sold 15.71% of its 20.70% stake to several buyers, including Shanghai Maitake 7.31% (Shanghai Shanshi Capital is the executive partner, with equity penetration from the Shanghai Finance Bureau, Shanghai State-owned Assets Supervision and Administration Commission, etc.), We'Tron Capital Limited 7.31%, and an investment platform under the management team of MicroPort 1.08%. Otsuka continues to hold about 5% of the shares. CICC pointed out that Shanshi Capital is an active fund management platform under the Shanghai State-owned Assets Supervision and Administration Commission, and this investment reflects the recognition of state-owned capital for MicroPort Group's assets, which is expected to help the company's core business expansion and potential strategic mergers and acquisitions, as well as improve the company's governance level. In addition, the original important shareholder We'Tron Capital Limited and the management team have both increased their holdings, which means that the interests of core shareholders and the management team are further deeply bound to the company

According to Zhitong Finance APP, MICROPORT (00853) has risen over 6% again, with a cumulative increase of over 70% in the past seven trading days. As of the time of writing, it has risen by 2.11%, priced at HKD 14.52, with a transaction volume of HKD 266 million.

In terms of news, on July 25, MICROPORT's largest shareholder, Otsuka Medical Devices, sold 15.71% of its 20.70% stake to several buyers, including Shanghai Maitake 7.31% (Shanghai Shanshi Capital is the executing partner, with equity penetration from the Shanghai Finance Bureau, Shanghai State-owned Assets Supervision and Administration Commission, etc.), We'Tron Capital Limited 7.31%, and an investment platform under the management of MICROPORT's management team 1.08%. Otsuka continues to hold about 5% of the shares.

CICC pointed out that Shanshi Capital is an active fund management platform under the Shanghai State-owned Assets Supervision and Administration Commission. This investment reflects the recognition of state-owned capital for MICROPORT Group's assets, which is expected to help the company expand its core business and potential strategic mergers and acquisitions, as well as improve corporate governance. In addition, the original important shareholders We'Tron Capital Limited and the management team have both increased their holdings, indicating a deeper binding of interests between core shareholders, the management team, and the company

### Related Stocks

- [00853.HK - MICROPORT](https://longbridge.com/en/quote/00853.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| MicroPort CardioFlow Merges with MicroPort CRM | MicroPort CardioFlow has merged with MicroPort CRM to create a comprehensive platform focused on structural heart, cardi | [Link](https://longbridge.com/en/news/275426231.md) |
| Golf-Woods won't rule out playing in this year's Masters | Tiger Woods, recovering from back surgery, has not ruled out competing in this year's Masters from April 9-12. Speaking  | [Link](https://longbridge.com/en/news/276159930.md) |
| Genxone Offer For Microbiome Sequencing Services Chosen As Most Favorable In Tender | Genxone SA :OFFER FOR MICROBIOME SEQUENCING SERVICES CHOSEN AS MOST FAVORABLE IN TENDER BY NATIONAL INSTITUTE OF GERIATR | [Link](https://longbridge.com/en/news/276140489.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |
| AgelessRx Expands Access to Multi-Cancer Early Detection Solutions, in Honor of Cancer Prevention Month | AgelessRx is expanding access to its multi-cancer early detection solutions in honor of Cancer Prevention Month. This in | [Link](https://longbridge.com/en/news/276180967.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.